Total Payments
$125,254
2024 Payments
$17,261
Companies
10
Transactions
121
Payment Breakdown by Category
Consulting$108,872 (86.9%)
Travel$6,933 (5.5%)
Other$6,000 (4.8%)
Research$2,317 (1.9%)
Food & Beverage$741.09 (0.6%)
Education$390.00 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $108,872 | 65 | 86.9% |
| Travel and Lodging | $6,933 | 24 | 5.5% |
| Honoraria | $3,500 | 1 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500 | 1 | 2.0% |
| Unspecified | $2,317 | 9 | 1.9% |
| Food and Beverage | $741.09 | 20 | 0.6% |
| Education | $390.00 | 1 | 0.3% |
Payments by Type
General
$122,936
112 transactions
Research
$2,317
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33,229 | 39 | $0 (2024) |
| Gilead Sciences, Inc. | $32,295 | 28 | $0 (2024) |
| ViiV Healthcare Company | $21,353 | 10 | $0 (2024) |
| Janssen Products, LP | $12,300 | 17 | $0 (2022) |
| Theratechnologies Inc. | $10,455 | 9 | $0 (2022) |
| GlaxoSmithKline, LLC. | $9,591 | 4 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $3,613 | 4 | $0 (2021) |
| Astellas Pharma Global Development | $1,465 | 8 | $0 (2021) |
| F. Hoffmann-La Roche AG | $852.94 | 1 | $0 (2021) |
| COMSORT, Inc | $100.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,261 | 7 | GlaxoSmithKline, LLC. ($8,091) |
| 2023 | $13,560 | 9 | ViiV Healthcare Company ($10,265) |
| 2022 | $23,295 | 22 | Janssen Products, LP ($12,300) |
| 2021 | $16,988 | 14 | Gilead Sciences, Inc. ($5,280) |
| 2020 | $12,457 | 12 | Merck Sharp & Dohme Corporation ($5,500) |
| 2019 | $15,923 | 23 | Gilead Sciences, Inc. ($7,579) |
| 2018 | $12,897 | 15 | Merck Sharp & Dohme Corporation ($11,847) |
| 2017 | $12,873 | 19 | Merck Sharp & Dohme Corporation ($6,917) |
All Payment Transactions
121 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,225.00 | General |
| 10/02/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 10/02/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,565.84 | General |
| 10/02/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 03/19/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,960.00 | General |
| 02/28/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 10/03/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,716.48 | General |
| 10/03/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 09/12/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: COVID-19 | ||||||
| 09/07/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: COVID-19 | ||||||
| 03/29/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,085.22 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,084.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,084.89 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/17/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 03/16/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $1,798.11 | General |
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/20/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $225.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/02/2022 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $1,884.57 | General |
| 12/02/2022 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/24/2022 | Janssen Products, LP | SYMTUZA (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $976.83 | 5 |
| SAFETY AND EFFICACY OF TOCILIZUMAB 4 MGKG OR 8 MGKG IN HOSPITALIZED PATIENTS WITH MODERATE-TO-SEVERE COVID-19 PNEUMONIA A RANDOMIZED CLINICAL TRIAL | F. Hoffmann-La Roche AG | $852.94 | 1 |
| A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $487.71 | 3 |
About Dr. Grace Mccomsey, MD
Dr. Grace Mccomsey, MD is a Infectious Disease healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720004336.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Grace Mccomsey, MD has received a total of $125,254 in payments from pharmaceutical and medical device companies, with $17,261 received in 2024. These payments were reported across 121 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($108,872).
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease, Pediatric Infectious Diseases
- Location Cleveland, OH
- Active Since 07/15/2006
- Last Updated 07/06/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1720004336
Products in Payments
- SYMTUZA (Drug) $15,913
- DELSTRIGO (Drug) $10,425
- Biktarvy (Drug) $5,040
- EGRIFTA (Drug) $4,205
- MK-8591A (Drug) $3,850
- CRESEMBA (Drug) $1,465
- MK-8591 (Drug) $1,225
- Actemra (Biological) $852.94
- ZERBAXA (Drug) $100.00
- Veklury (Drug) $40.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Cleveland
Steven Gordon, Md, MD
Infectious Disease — Payments: $161,172
Infectious Disease $161,172
Melissa Jenkins, Md, MD
Infectious Disease — Payments: $159,244
Infectious Disease $159,244
Alan Jay Taege, Md, MD
Infectious Disease — Payments: $107,534
Infectious Disease $107,534
Dr. Robin Jump, Md, Phd, MD, PHD
Infectious Disease — Payments: $56,857
Infectious Disease $56,857
Dr. Robert Bonomo, Md, MD
Infectious Disease — Payments: $52,004
Infectious Disease $52,004
Ann Avery, Md, MD
Infectious Disease — Payments: $46,295
Infectious Disease $46,295